tachyarrhythmias included atrial fibrillation in 34 participants, atrial flutter in 14 participants, and atrial tachycardia in 3 participants.
In-hospital mortality by COVID status in those with and without atrial tachyarrhythmia is shown in Table 2. Individuals who were COVID+ with new onset atrial tachyarrhythmia had the highest in-hospital mortality (50%) of any group (p=0.01). When compared to those who were COVID- without new onset atrial tachyarrhythmia, individuals who were COVID+ with new onset atrial tachyarrhythmia had higher in-hospital mortality in both unadjusted (OR 4.4 , 95% CI 1.8 to 10.7) and multivariable adjusted (OR 5.0, 95% CI 1.9 to 13.5) models. Individuals who were COVID- with new onset atrial tachyarrhythmia also had increased in-hospital mortality when compared to those who were COVID- without new onset atrial tachyarrhythmia after multivariable adjustment (OR 2.3, 95% CI 1.1 to 5.0). although the magnitude of this association was less than for those who were COVID+ with new onset atrial tachyarrhythmia.
The demographic and clinical characteristics and inpatient therapies for individuals with atrial tachyarrhythmias are shown in Table 3. Those who were COVID+ and developed an atrial tachyarrhythmia were more likely to require vasopressors (91% vs 47%, p=0.001), had a longer duration on vasopressors (9 ± 6 vs 2 ± 2 days, p=0.0001), were more likely to require mechanical ventilation (94% vs 42%, p=0.0001), had a longer duration of mechanical ventilation (18 ± 11 vs 4 ± 9 days, p=0.0001), had longer ICU lengths of stay (LOS) (23 ± 8 vs 12 ± 11 days, p=0.0001),